Enterome is a clinical-stage company developing off-the-shelf, transformational cancer treatments targeting a wide range of tumor types types (Glioblastoma, adrenal tumors, non-Hodgkin lymphoma and colorectal cancer). Phase 2 trials of our programs, EO2463, EO4010 and EO2401, have shown promising efficacy with good safety profiles in over 240 patients.
Enterome’s OncoMimics™ approach generates a powerful, long-lasting immune response from the patient’s own effector memory T cells, effectively overcoming immune tolerance to self-antigens.
